Strategic Partnering to Evaluate Cancer Signatures SPECS II (U01) | Apply Online

Opportunity Summary:

Strategic Partnering to Evaluate Cancer Signatures (SPECS II) is a National Cancer Institute (NCI) funding opportunity that focuses on moving multi-analyte molecular "signatures" from large-scale tumor profiling into practical clinical use. The core idea is that tumors can be characterized far more completely when data on DNA changes, RNA expression, and protein-level alterations are integrated, and that these combined profiles can yield signatures that correlate with clinically meaningful outcomes. While research efforts have shown that certain molecular patterns line up with important cancer features (such as prognosis, likelihood of recurrence, or response to therapy), the difficult step is translating those patterns into tools clinicians can reliably use when making treatment decisions. This program is aimed squarely at that translation gap.

The FOA encourages teams to build strategic partnerships that combine the different kinds of expertise required for real-world clinical application. That typically implies multidisciplinary collaboration spanning clinical oncology, pathology and biospecimen handling, genomics/transcriptomics/proteomics platforms, biostatistics and computational biology, assay development and quality control, and clinical trial operations. The intent is not just to generate more molecular data, but to determine how comprehensive molecular analyses can be turned into robust, interpretable signatures that are feasible in clinical settings and that can ultimately improve patient care and patient outcomes. Because this is a cooperative agreement mechanism (U01), applicants should expect substantial programmatic involvement from NIH/NCI compared with a standard investigator-initiated research grant, reflecting the emphasis on coordinated, milestone-driven efforts and shared goals.

A major stated deliverable of SPECS II is the production of publications and high-value datasets that are made available and accessible to the broader scientific community. The program is designed to support downstream progress in the design and conduct of future clinical trials, including trials that incorporate molecular signatures prospectively or larger clinical validation studies that test signature performance rigorously. In other words, this initiative is positioned to create a foundation others can build on: reusable evidence, transparent methods, and data resources that help the field decide which signatures are ready for broader clinical testing. At the same time, the FOA explicitly notes an interest in encouraging appropriate commercialization where it benefits public health, signaling that assays, software, or diagnostic approaches that emerge from the work should be considered for real-world deployment pathways when justified.

Administratively, the opportunity is listed as PAR-11-151 under NIH, within the cancer research CFDA programs (93.394 Cancer Detection and Diagnosis Research and 93.395 Cancer Treatment Research). It is categorized as discretionary funding and uses the cooperative agreement funding instrument. The opportunity was posted March 14, 2011, with an original and current closing date of June 15, 2012, and an archive date of July 16, 2012, indicating it is a past (archived) solicitation rather than an active one. The listed award ceiling is $680,000, and there is no cost sharing or matching requirement.

Eligibility is broad and includes many organization types that commonly participate in translational cancer research collaborations: nonprofit organizations (including 501(c)(3) and non-501(c)(3)), public and private institutions of higher education, state governments, small businesses, and for-profit organizations (other than small businesses). The FOA also allows participation from a range of specialized institutions and entities, including Historically Black Colleges and Universities (HBCUs), Hispanic-serving institutions, Tribally Controlled Colleges and Universities (TCCUs), Alaska Native and Native Hawaiian Serving Institutions, U.S. territories or possessions, regional organizations, and eligible federal agencies. Foreign organizations are eligible as non-domestic entities, and foreign components are allowed on applications submitted by U.S. organizations, reflecting the program’s openness to international expertise and resources where appropriate.

Overall, SPECS II is best understood as a structured push to turn comprehensive tumor molecular annotation into clinically actionable, multi-marker signatures through strategically assembled partnerships, with strong expectations around rigor, translational relevance, data sharing, and enabling the next generation of signature-driven clinical trials and validation efforts.

Browse more opportunities from the same agency: National Institutes of Health

Browse more opportunities from the same category: Education Health

Next opportunity: BLM CA Moreno Shale Formation Rare Earth Element Project

Previous opportunity: Cooperative Agreement to Support State Assessment Initiatives

USGrants.org Applicant Portal:

Are you interested in learning about about how to apply for this government funding opportunity? You can create a free applicant account and receive instant access to our applicant portal that many business owners like you have benefited from.

Apply for PAR 11 151

 

[Watch] how do funding administrators access proposals?

Applicants also applied for:

Applicants who have applied for this opportunity (PAR 11 151) also looked into and applied for these:

 

Grant application guides and resources

It is always free to apply for government grants. However the process may be very complex depending on the funding opportunity you are applying for. Let us help you!

Apply for Grants

 

 

Premium leads for funding administrators, grant writers, and loan issuers

Thousands of people visit our website for their funding needs every day. When a user creates a grant proposal and files for submission, we pass the information on to funding administrators, grant writers, and government loan issuers.

If you manage government grant programs, provide grant writing services, or issue personal or government loans, we can help you reach your audience.

Subscribe to Leads

 

Request more information:

Would you like to learn more about this funding opportunity, similar opportunities to "PAR 11 151", eligibility, application service, and/or application tips? Submit an inquiry below:

Don't forget to subscribe to our grant alerts mailing list to receive weekly alerts on new and updated grant funding opportunities like this one in your email.